Jonathan I Silverberg
Overview
Explore the profile of Jonathan I Silverberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
590
Citations
12051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cork M, Deleuran M, Geng B, Silverberg J, Simpson E, Stein Gold L, et al.
J Allergy Clin Immunol Pract
. 2025 Mar;
PMID: 40081761
Background: Abrocitinib has a manageable long-term safety profile for patients with moderate-to-severe atopic dermatitis. Identifying populations at higher risk of adverse events (AEs) will help optimize dose selection. Objective: To...
2.
Gooderham M, Molin S, Bissonnette R, Worm M, Crepy M, Stingeni L, et al.
J Am Acad Dermatol
. 2025 Mar;
PMID: 40081663
Background: There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE). Objective: To evaluate the long-term safety and efficacy of...
3.
Silverberg J, Anderson P, Cappelleri J, Piercy J, Levenberg M, Myers D, et al.
Arch Dermatol Res
. 2025 Mar;
317(1):556.
PMID: 40072609
Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in...
4.
Eichenfield D, Knapp K, Claxton A, Munoz B, Crawford J, Balu S, et al.
Dermatitis
. 2025 Feb;
PMID: 39969951
In the United States, 40-50% of patients with atopic dermatitis (AD) have moderate-to-severe disease, often necessitating advanced systemic therapies (ASTs; biologics or Janus kinase inhibitors). TARGET-DERM AD is an observational,...
5.
Silverberg J, Bieber T, Paller A, Beck L, Kamata M, Puig L, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(3):615-633.
PMID: 39953372
Introduction: A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe...
6.
Narla S, Fuxench Z, Abuabara K, Beck L, Chovatiya R, Thaci D, et al.
Dermatitis
. 2025 Feb;
PMID: 39925116
What defines long-term control in atopic dermatitis (AD) and why is it difficult to measure in AD? Why does long-term control matter? Herein, we critically examine these questions along with...
7.
Horeczko J, Alexis A, Silverberg J
Dermatitis
. 2025 Feb;
PMID: 39925114
Atopic dermatitis (AD) presents with a wide range of clinical manifestations with variable distribution, morphology, chronicity, and severity that may differ across ethnic and racial groups. A scoping literature review...
8.
Silverberg J, Simpson E, Pink A, Weidinger S, Chan G, Biswas P, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):367-380.
PMID: 39903335
Introduction: Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc...
9.
Silverberg J, Eichenfield L, Blauvelt A, Irvine A, Guttman-Yassky E, Langley R, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39847538
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety...
10.
Fonseca D, Japel M, Gyamfi M, Filgueiras I, Baiochi G, Ostrinski Y, et al.
NPJ Syst Biol Appl
. 2025 Jan;
11(1):7.
PMID: 39805853
Coronavirus disease 2019 (COVID-19) presents a wide spectrum of symptoms, the causes of which remain poorly understood. This study explored the associations between autoantibodies (AABs), particularly those targeting G protein-coupled...